Obacunone potentiated PD-1 immunotherapy in pancreatic cancer by mediating CD36
European Journal of Pharmacology · 2025
DOI: 10.1016/j.ejphar.2025.177367 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Chun-Yan Sang und 8 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemi…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Programmed Cell Death 1 Receptor, Immunotherapy, CD36 Antigens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Key Science and Technology Program of Shaanxi Province, National Natural Science Foundation of China, Chinese Academy of Sciences.
Abstract (Originalsprache)
Chemotherapy for patients with pancreatic cancer typically has a poor prognosis. Immunotherapy is currently a hot therapeutical approach to treat tumors. Various studies have shown that natural products have numerous activities, especially in the anti-tumor field. The triterpenoid class compound Obacunone has been shown to have various bioactivities, including anti-cancer properties. In this study, combining Obacunone with anti-PD-1 to treat pancreatic cancer in mice enhanced the anti-cancer activity of anti-PD-1 and suppressed tumor growth significantly. Proteomic analysis, immunofluorescence, Western blot, and flow cytometry revealed that this combination of compounds modulated the CD36-mediated PPAR signaling pathway to improve the infiltration and number of immune-associated CD4+ and CD8+ T cells in tumors. This report provides a new strategy for discovering immunotherapy for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, China.
- Department of Medicine, Northwest Minzu University, Lanzhou, 730030, China.
- Agricultural & Natural Resources College, University of Tehran, Karaj, Iran.
- S.Yu.Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences, Tashkent, 100170, Uzbekistan.
- Namangan Institute of Engineering and Technology, Kosonsoy 7, Namangan, 160115, Uzbekistan.
- CAS Key Laboratory of Chemistry of Northwestern Plant Resources and Key Laboratory for Natural Medicine of Gansu Province, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (CAS), Lanzhou, 730000, China…
Förderung
- Key Science and Technology Program of Shaanxi Province
- National Natural Science Foundation of China
- Chinese Academy of Sciences
Zitieren
APA
Sang, C. Y., Liu, J. R., Zheng, Y. D., Chai, T., Shi, J. T., Naghavi, M. R., Alibekovna, K. E., Solievich, B. A., & Yang, J. L. (2025). Obacunone potentiated PD-1 immunotherapy in pancreatic cancer by mediating CD36. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.177367
Vancouver
Sang CY, Liu JR, Zheng YD, Chai T, Shi JT, Naghavi MR, et al. Obacunone potentiated PD-1 immunotherapy in pancreatic cancer by mediating CD36. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.177367
BibTeX
@article{Sang2025,
author = {Sang, Chun-Yan and Liu, Jia-Rong and Zheng, Yi-Dan and Chai, Tian and Shi, Jiao-Tai and Naghavi, Mohammad Reza and Alibekovna, Komila Eshbakova and Solievich, Boymirzaev Azamat and Yang, Jun-Li},
title = {Obacunone potentiated PD-1 immunotherapy in pancreatic cancer by mediating CD36},
journal = {European Journal of Pharmacology},
year = {2025},
doi = {10.1016/j.ejphar.2025.177367}
}
EUVIMED